Mymd Pharmaceuticals (NASDAQ:QCLS) Announces Quarterly Earnings Results

Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, FiscalAI reports.

Mymd Pharmaceuticals Stock Performance

Shares of NASDAQ QCLS opened at $0.31 on Monday. The company has a market capitalization of $2.54 million, a price-to-earnings ratio of -0.09 and a beta of 2.21. The business’s 50 day moving average price is $0.71. Mymd Pharmaceuticals has a 1-year low of $0.30 and a 1-year high of $8.17.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on QCLS. Weiss Ratings raised Mymd Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday. Wall Street Zen raised Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

View Our Latest Stock Analysis on Mymd Pharmaceuticals

About Mymd Pharmaceuticals

(Get Free Report)

MyMD Pharmaceuticals is a clinical-stage biopharmaceutical company that has focused on developing treatments for inflammatory and age-related conditions. Its work has centered on drug candidates intended to address diseases for which existing treatment options may be limited. The company’s lead candidate, MYMD-1, is an investigational oral therapy designed to regulate inflammatory processes and the immune system. MyMD has studied its potential application across a range of chronic conditions; it is not an approved medicine.

Read More

Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.